You have full access to this article via your institution.
Around a year ago — before Delta and other variants entered the COVID-19 lexicon — virologists Theodora Hatziioannou and Paul Bieniasz, both at Rockefeller University in New York City, set out to make a version of a key SARS-CoV-2 protein with the ability to dodge all the infection-blocking antibodies our body makes.
The goal was to identify the parts of spike — the protein SARS-CoV-2 uses to infect cells — that are targeted by these neutralizing antibodies in order to map a key part of our body’s attack on the virus. So the researchers mixed and matched potentially concerning mutations identified in lab experiments and circulating viruses, and tested their Franken-spikes in harmless ‘pseudotype’ viruses incapable of causing COVID-19. In a study published this September in Nature1, they reported that a spike mutant containing 20 changes was fully resistant to neutralizing antibodies made by most of the people tested who had been either infected or vaccinated — but not to everyone’s.
Those who had recovered from COVID-19 months before receiving their jabs harboured antibodies capable of defanging the mutant spike, which displays far more resistance to immune attack than any known naturally occurring variant. These peoples’ antibodies even blocked other types of coronaviruses. “It’s very likely they will be effective against any future variant that SARS-CoV-2 throws against them,” says Hatziioannou.
As the world watches out for new coronavirus variants, the basis of such ‘super-immunity’ has become one of the pandemic’s great mysteries. Researchers hope that, by mapping the differences between the immune protection that comes from infection compared with that from vaccination, they can chart a safer path to this higher level of protection.
“It has implications on boosters and how our immune responses are primed for the next variant that emerges,” says Mehul Suthar, a virologist at Emory University in Atlanta, Georgia. “We’re flying by the seat of our pants trying to figure this stuff out.”
Not long after countries began rolling out vaccines, researchers started noticing unique properties of the vaccine responses of people who had previously caught and recovered from COVID-19. “We saw that the antibodies come up to these astronomical levels that outpace what you get from two doses of vaccine alone,” says Rishi Goel, an immunologist at the University of Pennsylvania in Philadelphia who is part of a team studying super-immunity — or ‘hybrid immunity’, as most scientists call it.
Initial studies of people with hybrid immunity found that their serum — the antibody-containing portion of blood — was far better able to neutralize immune-evading strains, such as the Beta variant identified in South Africa, and other coronaviruses, compared with ‘naive’ vaccinated individuals who had never encountered SARS-CoV-22. It wasn’t clear whether this was just due to the high levels of neutralizing antibodies, or to other properties.
The most recent studies suggest that hybrid immunity is, at least partly, due to immune players called memory B cells. The bulk of antibodies made after infection or vaccination come from short-lived cells called plasmablasts, and antibody levels fall when these cells inevitably die-off. Once plasmablasts are gone, the main source of antibodies becomes much rarer memory B cells that are triggered by either infection or vaccination.
Some of these long-lived cells make higher-quality antibodies than plasmablasts, says Michel Nussenzweig, an immunologist at the Rockefeller. That’s because they evolve in organs called lymph nodes, gaining mutations that help them to bind more tightly to the spike protein over time. When people who recovered from COVID-19 are re-exposed to SARS-CoV-2’s spike, these cells multiply and churn out more of these highly potent antibodies.
“You get a sniff of antigen, in this case of mRNA vaccine, and those cells just explode,” says Goel. In this way, a first vaccine dose in someone who has previously been infected is doing the same job as a second dose in someone who has never had COVID-19.
Differences between the memory B cells triggered by infection and those triggered by vaccination — as well as the antibodies they make — might also underlie the heightened responses of hybrid immunity. Infection and vaccination expose the spike protein to the immune system in vastly different ways, Nussenzweig says.
In a series of studies3,4,5, Nussenzweig’s team, which includes Hatziioannou and Bieniasz, compared the antibody responses of infected and vaccinated people. Both lead to the establishment of memory B cells that make antibodies that have evolved to become more potent, but the researchers suggest this occurs to a greater extent after infection.
The team isolated hundreds of memory B cells — each making a unique antibody — from people at various time points after infection and vaccination. Natural infection triggered antibodies that continued to grow in potency and their breadth against variants for a year after infection, whereas most of those elicited by vaccination seemed to stop changing in the weeks after a second dose. Memory B cells that evolved after infection were also more likely than those from vaccination to make antibodies that block immune-evading variants such as Beta and Delta.
A separate study found that, compared with mRNA vaccination, infection leads to a pool of antibodies that recognize variants more evenly by targeting diverse regions of spike6. The researchers also found that people with hybrid immunity produced consistently higher levels of antibodies, compared with never-infected vaccinated people, for up to 7 months. Antibody levels were also more stable in people with hybrid immunity, report the team led by immunologist Duane Wesemann, at Harvard Medical School in Boston, Massachusetts.
Many studies of hybrid immunity haven’t followed naive vaccine recipients for as long as those who recovered from COVID, and it’s possible their B cells will make antibodies that gain potency and breadth with more time, additional vaccine doses, or both, researchers say. It can take months for a stable pool of memory B cells to establish itself and mature.
“It’s not surprising that people infected and vaccinated are getting a nice response,” says Ali Ellebedy, a B-cell immunologist at Washington University in St. Louis, Missouri. “We are comparing someone who started the race three to four months ago to someone who started the race now.”
There is some evidence that people who received both jabs without previously being infected seem to be catching up. Ellebedy’s team collected lymph-node samples from mRNA-vaccinated individuals and found signs that some of their memory B cells triggered by the vaccination were gaining mutations, up to 12 weeks after the second dose, that enabled them to recognize diverse coronaviruses, including some that cause common colds7.
Goel, University of Pennsylvania immunologist John Wherry and their colleagues found signs that six months after vaccination, memory B cells from naive individuals were continuing to grow in number and evolve greater capacity to neutralize variants8. Antibody levels fell after vaccination, but these cells should start cranking out antibodies if they encounter SARS-CoV-2 again. “The reality is you have a pool of high-quality memory B cells that are there to protect you if you ever see this antigen again,” Goel says.
A third vaccine dose might allow people who haven’t been infected to achieve the benefits of hybrid immunity, says Matthieu Mahévas, an immunologist at the Necker Institute for Sick Children in Paris. His team found that some of the memory B cells from naive vaccine recipients could recognize Beta and Delta, two months after vaccination9. “When you boost this pool, you can clearly imagine you will generate potent neutralizing antibodies against variants,” Mahévas says.
Extending the interval between vaccine doses could also mimic aspects of hybrid immunity. In 2021, amid scarce vaccine supplies and a surge in cases, officials in the Canadian province of Quebec recommended a 16-week interval between first and second doses (since reduced to 8 weeks).
A team co-led by Andrés Finzi, a virologist at the University of Montreal, Canada, found that people who received this regimen had SARS-CoV-2 antibody levels similar to those in people with hybrid immunity10. These antibodies could neutralize a swathe of SARS-CoV-2 variants — as well as the virus behind the 2002–4 SARS epidemic. “We are able to bring naive people to almost the same level as previously infected and vaccinated, which is our gold standard,” says Finzi.
Understanding the mechanism behind hybrid immunity will be key to emulating it, say scientists. The latest studies focus on antibody responses made by B cells, and it’s likely that T-cell responses to vaccination and infection behave differently. Natural infection also triggers responses against viral proteins other than spike — the target of most vaccines. Nussenzweig wonders whether other factors unique to natural infection are crucial. During infection, hundreds of millions of viral particles populate the airways, encountering immune cells that regularly visit nearby lymph nodes, where memory B cells mature. Viral proteins stick around in the gut of some people months after recovery, and it’s possible that this persistence helps B cells hone their responses to SARS-CoV-2.
Researchers say that it is also important to determine the real-world effects of hybrid immunity. A study from Qatar suggests that people who get Pfizer-BioNTech’s mRNA vaccine after infection are less likely to test positive for COVID-19 than are individuals with no history of infection11. Hybrid immunity might also be responsible for falling case numbers across South America, says Gonzalo Bello Bentancor, a virologist at the Oswaldo Cruz Institute in Rio de Janeiro. Many South American countries experienced very high infection rates earlier in the pandemic, but have now vaccinated a large proportion of their populations. It’s possible that hybrid immunity is better than the immunity from vaccination alone at blocking transmission, says Bello Bentancor.
As breakthrough infections caused by the Delta variant stack up, researchers including Nussenzweig are keen to study the immunity in people who were infected after their COVID-19 vaccinations, rather than before. An individual’s first exposure to influenza virus biases their responses to subsequent exposures and vaccinations — a phenomenon called original antigenic sin — and researchers want to know if this occurs with SARS-CoV-2.
Those studying hybrid immunity stress that — whatever the potential benefits — the risks of a SARS-CoV-2 infection mean that it should be avoided. “We are not inviting anybody to get infected and then vaccinated to have a good response,” says Finzi. “Because some of them will not make it through.”
Schmidt, F. et al. Nature https://doi.org/10.1038/s41586-021-04005-0 (2021).
Stamatatos, L. et al. Science 372, 1413-1418 (2021).
Gaebler, C. et al. Nature 591, 639–644 (2021).
Wang, Z. et al. Nature 595, 426–431 (2021).
Cho, A. et al. Nature https://doi.org/10.1038/s41586-021-04060-7 (2021).
Chen, Y. et al. Preprint at bioRxiv: https://doi.org/10.1101/2021.09.09.459504 (2021).
Turner, J. S. et al. Nature 596, 109–113 (2021).
Goel, R. R. et al. Preprint at bioRxiv: https://doi.org/10.1101/2021.08.23.457229 (2021).
Sokal, A. et al. Immunity https://doi.org/10.1016/j.immuni.2021.09.011 (2021).
Tauzin, A. et al. Preprint at medRxiv: https://doi.org/10.1101/2021.09.17.21263532 (2021).
Abu-Raddad, L. J. et al. Preprint at medRxiv: https://doi.org/10.1101/2021.07.25.21261093 (2021).